SOR-102 is under clinical development by Sorriso Pharmaceuticals and currently in Phase I for Ulcerative Colitis. According to GlobalData, Phase I drugs for Ulcerative Colitis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SOR-102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SOR-102 overview
SOR-102 is under development for the treatment of ulcerative colitis. The therapeutic candidate is bispecific antibody administered orally. It acts by targeting tumor necrosis factor alpha and interleukin 23 (IL-23).
Sorriso Pharmaceuticals overview
Sorriso Pharmaceuticals (Sorriso Pharma) is a biotechnology company that develops therapies to treat inflammatory disease, including Crohn’s disease and ulcerative colitis. The company is headquartered in Salt Lake City, Utah, the US.
For a complete picture of SOR-102’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
